Comparison of Cerebrospinal Fluid Amyloidogenic Nanoplaques With Core Biomarkers of Alzheimer's Disease.
Alzheimer disease
amyloid
amyloid beta-peptides
amyloidogenic proteins
biomarkers
cerebrospinal fluid
fluorescence spectrometry
thioflavin T
Journal
Frontiers in aging neuroscience
ISSN: 1663-4365
Titre abrégé: Front Aging Neurosci
Pays: Switzerland
ID NLM: 101525824
Informations de publication
Date de publication:
2020
2020
Historique:
received:
21
09
2020
accepted:
09
12
2020
entrez:
25
1
2021
pubmed:
26
1
2021
medline:
26
1
2021
Statut:
epublish
Résumé
Accurate biomarkers of Alzheimer's disease (AD) are essential for early diagnosis and intervention. Available biomarkers are not sufficient to permit the monitoring of AD progression over time, and additional biomarkers are required. Measures of aggregated amyloid-β (Aβ) could be useful biomarkers for AD. Here, we investigate whether levels of Thioflavin-T (ThT) positive amyloid aggregates, i.e., nanoplaques, in cerebrospinal fluid (CSF) could serve as useful biomarkers for AD. One-hundred and eighteen memory clinic patients were AT(N) classified, and CSF nanoplaque concentrations were compared between patients on the "Alzheimer's continuum" (A+ patients) and patients with "Normal AD biomarkers" or "Non-AD pathologic change" (A- patients). CSF nanoplaque concentrations and sizes were quantified using the novel ThT-Fluorescence Correlation Spectroscopy (ThT-FCS) assay, and core biomarkers (Aβ
Identifiants
pubmed: 33488383
doi: 10.3389/fnagi.2020.608628
pmc: PMC7820807
doi:
Types de publication
Journal Article
Langues
eng
Pagination
608628Informations de copyright
Copyright © 2021 Aksnes, Tiiman, Edwin, Terenius, Bogdanović, Vukojević and Knapskog.
Déclaration de conflit d'intérêts
ABK and THE have worked on clinical trials for Roche (BN29553) and Boehringer-Ingelheim (1346.0023). AT, LT and VV have filed a patent application under the Patent Cooperation Treat (PCT) WO 2019/192969 A1 “Method for the Diagnosis of Amyloid-Associated Diseases.” The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Lancet Neurol. 2013 Feb;12(2):207-16
pubmed: 23332364
Br J Psychiatry. 1982 Jun;140:566-72
pubmed: 7104545
J Alzheimers Dis. 2016 Mar 29;52(2):417-20
pubmed: 27031492
Nat Commun. 2020 Mar 13;11(1):1377
pubmed: 32170138
Acta Neuropathol Commun. 2019 Jul 26;7(1):120
pubmed: 31349874
PLoS One. 2019 Aug 20;14(8):e0221365
pubmed: 31430334
Cold Spring Harb Perspect Med. 2012 Sep 01;2(9):a006221
pubmed: 22951438
Nucl Med Commun. 2017 Mar;38(3):234-241
pubmed: 27984539
J Alzheimers Dis. 2015;50(1):1-7
pubmed: 26639966
Alzheimers Dement. 2018 Apr;14(4):535-562
pubmed: 29653606
Tidsskr Nor Laegeforen. 2011 Nov 15;131(22):2254-7
pubmed: 22085955
J Psychiatr Res. 1975 Nov;12(3):189-98
pubmed: 1202204
Curr Alzheimer Res. 2009 Jun;6(3):285-9
pubmed: 19519310
Braz J Psychiatry. 2019 Nov-Dec;41(6):479-484
pubmed: 31166546
Alzheimers Dement. 2014 Nov;10(6):844-52
pubmed: 24798886
Brain. 2011 Sep;134(Pt 9):2456-77
pubmed: 21810890
BMC Neurol. 2020 Jan 9;20(1):10
pubmed: 31918679
JAMA. 2020 Aug 25;324(8):772-781
pubmed: 32722745
Ann Neurol. 2013 Apr;73(4):449-58
pubmed: 23625526
Biochemistry. 2015 Dec 15;54(49):7203-11
pubmed: 26574169
Alzheimers Dement. 2011 Jul;7(4):386-395.e6
pubmed: 21784349
Biochim Biophys Acta. 2008 Oct;1782(10):549-58
pubmed: 18760351
EMBO Mol Med. 2016 Jun 01;8(6):595-608
pubmed: 27025652
J Alzheimers Dis. 2015;46(4):1071-7
pubmed: 26402633
Alzheimers Dement. 2011 May;7(3):270-9
pubmed: 21514249
J Neurosci. 2014 Feb 19;34(8):2884-97
pubmed: 24553930
Nature. 2014 Nov 13;515(7526):274-8
pubmed: 25307057
Biophys J. 2003 Mar;84(3):1977-84
pubmed: 12609900
Proc Natl Acad Sci U S A. 2008 Nov 25;105(47):18176-81
pubmed: 19011092
R Soc Open Sci. 2017 Jan 4;4(1):160696
pubmed: 28280572
Alzheimer Dis Assoc Disord. 2014 Jul-Sep;28(3):206-18
pubmed: 24632990
Eur J Nucl Med Mol Imaging. 2009 Dec;36(12):2103-10
pubmed: 19838705
Chem Commun (Camb). 2018 Aug 14;54(66):9107-9118
pubmed: 29993065
J Intern Med. 2015 Sep;278(3):277-90
pubmed: 25752192
Nature. 2009 Oct 15;461(7266):916-22
pubmed: 19829371
Science. 1992 Apr 10;256(5054):184-5
pubmed: 1566067
Nat Med. 1998 Jul;4(7):832-4
pubmed: 9662376
J Biol Chem. 1999 Sep 3;274(36):25945-52
pubmed: 10464339
J Alzheimers Dis. 2012;29(1):171-6
pubmed: 22214781
PLoS One. 2013 Jun 14;8(6):e66381
pubmed: 23799095
Cell Mol Life Sci. 2019 May;76(10):1833-1863
pubmed: 30770953
Neurobiol Dis. 2018 Jan;109(Pt B):178-190
pubmed: 28709995
Neurobiol Aging. 2008 Oct;29(10):1456-65
pubmed: 17499392
Neurodegener Dis. 2009;6(4):139-47
pubmed: 19521063
J Alzheimers Dis. 2018;62(4):1595-1607
pubmed: 29504529
Clin Biochem. 2017 Dec;50(18):1061-1066
pubmed: 28860054
Aging Cell. 2020 Nov;19(11):e13258
pubmed: 33155752
J Alzheimers Dis. 2020;77(2):831-842
pubmed: 32741818
Methods Enzymol. 1999;309:274-84
pubmed: 10507030
J Alzheimers Dis. 2019;68(2):571-582
pubmed: 30814355
Nat Neurosci. 2018 Oct;21(10):1332-1340
pubmed: 30250260
Alzheimers Res Ther. 2011 Feb 17;3(1):5
pubmed: 21329517
Nat Commun. 2019 Apr 4;10(1):1541
pubmed: 30948723
Alzheimers Dement. 2015 Jan;11(1):58-69
pubmed: 24795085
J Biol Chem. 2016 Aug 5;291(32):16485-93
pubmed: 27325705
Int J Mol Sci. 2020 Jan 31;21(3):
pubmed: 32023927
Int J Alzheimers Dis. 2011;2011:151645
pubmed: 22114742
Alzheimers Dement. 2011 May;7(3):263-9
pubmed: 21514250
J Alzheimers Dis. 2009;18(1):89-102
pubmed: 19542628
Neurology. 2016 Aug 2;87(5):539-47
pubmed: 27371494
Acta Neuropathol. 2013 Nov;126(5):659-70
pubmed: 23812320
FASEB J. 2010 Aug;24(8):2716-26
pubmed: 20339023